Last reviewed · How we verify
NCT06291896
A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection
NA trial testing MammoWave in Women's Health: Neoplasm of Breast in 10,000 participants. Currently enrolling.
15 February 2026
Quick facts
| Lead sponsor | Umbria Bioengineering Technologies |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 10,000 |
| Start date | 15 March 2024 |
| Primary completion | 15 February 2026 |
| Estimated completion | 15 December 2026 |
| Sites | 9 locations across Italy, Poland, Switzerland, Portugal, Spain |
Drugs / interventions tested
- MammoWave
Conditions studied
- Women's Health: Neoplasm of Breast — all drugs for Women's Health: Neoplasm of Breast →
Sponsor
Umbria Bioengineering Technologies
Who can join
Adults 45 to 74, female only, with Women's Health: Neoplasm of Breast. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open, multicentric, interventional, prospective, non-randomized clinical investigation. The first aim of the study is to confirm that MammoWave reaches sensitivity\>75% and specificity\>90% in breast cancer (BC) detection on 10.000 volunteers undergoing regular screening programs.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Microwave imaging for breast cancer screening: protocol for an open, multicentric, interventional, prospective, non-randomised clinical investigation to evaluate cancer detection capabilities of MammoWave system on an asymptomatic population across multiple European countries.
Álvarez Sánchez-Bayuela D, Fernández Martín J, Tiberi G, Ghavami N, et al · · 2024 · cited 1× · PMID 39488412 · DOI 10.1136/bmjopen-2024-088431 -
A Line-Source Approach for Simulating MammoWave Microwave Imaging Apparatus for Breast Lesion Detection.
Ghavami N, Dudley S, Ghavami M, Tiberi G. · · 2025 · PMID 40573527 · DOI 10.3390/s25123640
Verify or expand the search:
- PubMed search for NCT06291896
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Umbria Bioengineering Technologies trials
Trials by the same sponsor.
- NCT05300464 — A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection · NA · recruiting
- NCT04622644 — Clinical Investigation to Evaluate the Suitability of StrokeWave in Distinguishing Haemorragic From Ischaemic Strokes · NA · completed
- NCT04253366 — Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06291896 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Umbria Bioengineering Technologies
- Last refreshed: 6 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06291896.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing